Edgestream Partners L.P. bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 24,752 shares of the biotechnology company’s stock, valued at approximately $1,620,000.
Several other institutional investors have also recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at approximately $1,208,838,000. Jupiter Topco LLC purchased a new position in Arrowhead Pharmaceuticals during the second quarter worth about $99,623,000. Janus Henderson Group PLC grew its holdings in shares of Arrowhead Pharmaceuticals by 12.2% in the first quarter. Janus Henderson Group PLC now owns 1,436,990 shares of the biotechnology company’s stock valued at $90,119,000 after acquiring an additional 156,544 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Arrowhead Pharmaceuticals in the second quarter worth $70,061,000. Finally, Renaissance Technologies LLC purchased a new position in Arrowhead Pharmaceuticals in the first quarter worth $64,988,000. Institutional investors and hedge funds own 62.61% of the company’s stock.
Arrowhead Pharmaceuticals Price Performance
ARWR stock opened at $41.36 on Friday. The firm has a market cap of $5.85 billion, a P/E ratio of -8.09 and a beta of 1.34. The firm’s fifty day moving average is $59.23 and its 200 day moving average is $70.33. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $37.43 and a 52 week high of $95.49. The company has a debt-to-equity ratio of 16.61, a quick ratio of 4.11 and a current ratio of 4.14.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on ARWR
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.
Featured Stories
- Five stocks we like better than Arrowhead Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report).
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
